On June 17^th, 2025, ZonhonBio's innovative Class 1 biologic drug ZHB118 sublingual tablets, independently developed with full intellectual property rights in China and globally, has received the "Clinical Trial Approval Notice" from China's National Medical Products Administration (NMPA). The approved indication covers desensitization therapy for adult patients with dog allergen-induced allergic rhinitis or rhinoconjunctivitis (with or without allergic asthma).